SAD and MAD study of VES001

2023-505847-38-00 Protocol CHDR2309 Human pharmacology (Phase I) - First administration to humans Ended

Start 11 Oct 2023 · End 26 Jul 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol CHDR2309

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 78
Countries 1
Sites 1

Frontotemporal dementia (FTD)

Key facts

Sponsor
Insusense ApS, Insusense ApS
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]
Trial duration
11 Oct 2023 → 26 Jul 2024
Decision date (initial)
2023-10-11
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Frontotemporal dementia (FTD)

VersionLevelCodeTermSystem organ class
21.1 PT 10068968 Frontotemporal dementia 100000004852

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Insusense ApS

Sponsor organisation
Insusense ApS
Address
Scherfigsvej 7
City
Copenhagen Oe
Postcode
2100
Country
Denmark

Scientific contact point

Organisation
Insusense ApS
Contact name
Centre For Human Drug Research

Public contact point

Organisation
Insusense ApS
Contact name
Centre For Human Drug Research

Insusense ApS

Sponsor organisation
Insusense ApS
Address
4th Floor, Hauser Plads 10 Hauser Plads 10
City
Copenhagen
Postcode
1127
Country
Denmark

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 78 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Centre for Human Drug Research
NA, Zernikedreef 8, 2333 CL, Leiden

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2023-10-11 2024-07-26 2023-10-19 2024-07-26

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-08-28 Netherlands Acceptable
2023-10-11
2023-10-11
2 NON SUBSTANTIAL MODIFICATION NSM-1 2023-11-29 Netherlands Acceptable
2023-10-11
2023-11-29
3 SUBSTANTIAL MODIFICATION SM-1 2024-03-20 Netherlands Acceptable
2024-04-15
2024-04-15